HC Wainwright Has Bullish Forecast for VYGR FY2024 Earnings

Voyager Therapeutics, Inc. (NASDAQ:VYGR) – Analysts at HC Wainwright lifted their FY2024 earnings per share estimates for shares of Voyager Therapeutics in a note issued to investors on Wednesday, November 13th. HC Wainwright analyst P. Trucchio now forecasts that the company will post earnings of ($0.82) per share for the year, up from their previous estimate of ($0.97). HC Wainwright has a “Buy” rating and a $30.00 price objective on the stock. The consensus estimate for Voyager Therapeutics’ current full-year earnings is ($1.12) per share. HC Wainwright also issued estimates for Voyager Therapeutics’ Q2 2025 earnings at ($0.31) EPS, FY2026 earnings at ($1.38) EPS, FY2027 earnings at ($1.32) EPS and FY2028 earnings at ($1.69) EPS.

Several other brokerages have also commented on VYGR. Wedbush dropped their price target on shares of Voyager Therapeutics from $8.00 to $7.00 and set a “neutral” rating for the company in a research report on Wednesday, August 7th. Leerink Partnrs raised Voyager Therapeutics to a “strong-buy” rating in a research report on Wednesday, October 16th. Canaccord Genuity Group reiterated a “buy” rating and issued a $14.00 target price on shares of Voyager Therapeutics in a report on Thursday. StockNews.com lowered Voyager Therapeutics from a “buy” rating to a “hold” rating in a research note on Sunday, November 10th. Finally, Leerink Partners started coverage on Voyager Therapeutics in a research note on Wednesday, October 16th. They issued an “outperform” rating and a $15.00 price objective on the stock. Two analysts have rated the stock with a hold rating, seven have given a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat, Voyager Therapeutics has an average rating of “Moderate Buy” and a consensus target price of $17.00.

Voyager Therapeutics Price Performance

Shares of VYGR stock opened at $5.64 on Monday. The firm’s 50-day simple moving average is $6.62 and its 200-day simple moving average is $7.49. Voyager Therapeutics has a 1-year low of $5.59 and a 1-year high of $11.72. The firm has a market cap of $308.11 million, a P/E ratio of 7.94 and a beta of 0.89.

Voyager Therapeutics (NASDAQ:VYGR) last released its earnings results on Tuesday, November 12th. The company reported ($0.16) earnings per share for the quarter, topping the consensus estimate of ($0.45) by $0.29. The firm had revenue of $24.63 million for the quarter, compared to the consensus estimate of $12.63 million. Voyager Therapeutics had a return on equity of 8.33% and a net margin of 15.80%. During the same period in the prior year, the business posted ($0.59) earnings per share.

Insider Activity

In other news, insider Sandell Jacquelyn Fahey sold 5,999 shares of the company’s stock in a transaction on Wednesday, October 2nd. The shares were sold at an average price of $5.82, for a total value of $34,914.18. Following the completion of the transaction, the insider now directly owns 86,001 shares in the company, valued at approximately $500,525.82. This represents a 6.52 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Insiders own 4.53% of the company’s stock.

Hedge Funds Weigh In On Voyager Therapeutics

Institutional investors have recently added to or reduced their stakes in the company. BNP Paribas Financial Markets increased its position in shares of Voyager Therapeutics by 198.6% during the first quarter. BNP Paribas Financial Markets now owns 48,769 shares of the company’s stock worth $454,000 after acquiring an additional 32,437 shares during the last quarter. Empowered Funds LLC raised its position in shares of Voyager Therapeutics by 8.2% in the 1st quarter. Empowered Funds LLC now owns 39,471 shares of the company’s stock valued at $367,000 after purchasing an additional 2,975 shares in the last quarter. ProShare Advisors LLC purchased a new position in shares of Voyager Therapeutics during the 1st quarter valued at approximately $101,000. Vanguard Group Inc. grew its position in shares of Voyager Therapeutics by 27.8% during the first quarter. Vanguard Group Inc. now owns 3,231,698 shares of the company’s stock worth $30,087,000 after buying an additional 702,030 shares in the last quarter. Finally, Acadian Asset Management LLC increased its stake in shares of Voyager Therapeutics by 10.1% in the first quarter. Acadian Asset Management LLC now owns 459,850 shares of the company’s stock worth $4,280,000 after buying an additional 42,029 shares during the last quarter. Institutional investors and hedge funds own 48.03% of the company’s stock.

Voyager Therapeutics Company Profile

Voyager Therapeutics, Inc, a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of alzheimer's disease. Its product pipeline includes superoxide dismutase 1 silencing gene therapy, which is in preclinical trial for the treatment of amyotrophic lateral sclerosis; tau silencing gene therapy, which is in preclinical trial for the treatment of alzheimer's disease; and vectorized anti-amyloid antibody, a gene therapy targeting anti-amyloid for the treatment of alzheimer's disease and is in preclinical trial.